Loading…
for educational and safety purposes
3-MeO-PCP and 3-MeO-PCE both come up in the same conversations; they overlap on Glutamate. 3-MeO-PCP: 3-MeO-PCP (3-methoxyphencyclidine) is a dissociative new psychoactive substance of the arylcyclohexylamine (phencyclidine) class. 3-MeO-PCE: 3-MeO-PCE (3-methoxyeticyclidine) is a methoxylated analog of eticyclidine (PCE) in the arylcyclohexylamine class that acts as an NMDA receptor antagonist, reportedly with higher NMDA receptor binding affinity than phencyclidine itself.
3-MeO-PCP (3-methoxyphencyclidine) is a dissociative new psychoactive substance of the arylcyclohexylamine (phencyclidine) class. It acts principally as an antagonist at the N-methyl-D-aspartate (NMDA) glutamate receptor and is additionally reported to inhibit monoamine reuptake, giving it a more stimulating and dopaminergic character than ketamine; the closely related analogs 4-MeO-PCP and 3-MeO-PCMo have been shown to engage the mesolimbic dopamine pathway to produce rewarding and reinforcing effects. It is considerably more potent and longer-acting than ketamine, which contributes to a narrow margin between recreational and toxic exposure. The compound has been implicated in numerous non-fatal intoxications and deaths, and its metabolism and analytical detection have been characterized in forensic casework and in silico ADME studies. Because standard phencyclidine immunoassays detect it inconsistently, laboratory confirmation generally relies on chromatographic and mass-spectrometric methods.
3-MeO-PCE (3-methoxyeticyclidine) is a methoxylated analog of eticyclidine (PCE) in the arylcyclohexylamine class that acts as an NMDA receptor antagonist, reportedly with higher NMDA receptor binding affinity than phencyclidine itself. Positioned within the PCP/PCE family, it tends to be more stimulating and disinhibiting than ketamine and has been implicated in fatal intoxications, typically in combination with other substances. Its in vitro and in vivo metabolism has been mapped in human liver microsomes, a zebrafish model, and authentic urine samples, proceeding through hydroxylation, O-demethylation, and N-dealkylation, with a hydroxylated metabolite proposed as a biomarker of use. It remains an obscure research chemical with limited controlled human data.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
antagonist
Antagonist
reuptake inhibitor
agonist
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.